Loading...
Market
First milestone achieved by AVMA by mid-2025?
2
Africa•Paris•French•Emmanuel Macron•African•African Vaccine Manufacturing Accelerator•AVMA•World Bank Group•Gavi•World Health Organization•WHO•African Union
Resolution / Starting Odds
Operational Initial Phase • 33%
First Vaccine Produced • 33%
First International Partnership • 34%
Official AVMA progress reports or announcements
Story
$1.2 Billion Initiative to Boost Vaccine Production in Africa Announced at Paris Summit
Jun 20, 2024, 12:59 PM
World leaders have announced a significant initiative to bolster vaccine production in Africa, highlighting the need for global cooperation in addressing health disparities exposed by the COVID-19 pandemic. At a Paris summit, French President Emmanuel Macron, alongside several African leaders, unveiled a $1.2 billion project aimed at accelerating the rollout of vaccines across the continent. This initiative includes the launch of the African Vaccine Manufacturing Accelerator (AVMA), supported by the World Bank Group and Gavi, which aims to enhance vaccine sovereignty and innovation in Africa. The World Health Organization (WHO) has also expressed its commitment to supporting the African Union's target of producing 60% of the continent's vaccines locally. Additionally, Gavi announced plans to expand global access to human rabies vaccines, targeting over 50 countries. The initiative was launched at Gavi's Global Forum for Vaccine Sovereignty & Innovation, which also aims to create a sustainable vaccine ecosystem in Africa. The project is part of a broader $1 billion effort to improve vaccine access.
View original story
Similar markets
Increased penalties • 25%
Public awareness campaigns • 25%
Animal rescue funding • 25%
Other • 25%
Economic policies • 25%
Social policies • 25%
Foreign policies • 25%
Other • 25%
Mass Deportations • 25%
Border Wall Completion • 25%
Visa Restrictions • 25%
Other • 25%
Vaccine testing reform • 25%
Chronic disease initiative • 25%
FDA/CDC restructuring • 25%
Other initiative • 25%
Personnel apparatus for policymakers • 25%
Policy development • 25%
Public engagement and outreach • 25%
Discontinued • 25%
Reducing government spending • 25%
Enhancing presidential power • 25%
Dismantling bureaucracy • 25%
Other • 25%
Anti-corruption • 25%
Community engagement • 25%
Crime reduction • 25%
Technology and innovation • 25%
Norway • 25%
Russia • 25%
United Nations • 25%
Other • 25%
Yes, nationwide adoption • 33%
Yes, partial adoption in some states • 33%
No adoption • 33%
Reduced disease incidence • 33%
Improved patient outcomes • 33%
Enhanced healthcare access • 33%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 completion • 25%
No significant milestone • 25%
